ArticleRisk management and healthcare policy2025
Financial Toxicity for Pembrolizumab and Atezolizumab for Metastatic Non-Small Cell Lung Cancer: A Pooled Analysis of Cost-Effectiveness Analyses.
Weijia Huang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.